🧬 Dr. Oren Beske shared insights on employing these enzymes creatively, impacting protein expression for biologics.
🌍 As biologics become complex, customized manufacturing platforms are essential for future developments. ATUM aims to enhance early-stage drug discovery and production processes.
Introduction:
The innovative advancements in transposase technology by the biotech company ATUM signify a major leap in cell line engineering, particularly for the manufacturing of biologics. By leveraging multiple transposase enzymes, ATUM aims to enhance genetic modifications in cell lines widely used in therapeutic applications.
- ATUM is pioneering the use of multiple transposase enzymes to engineer Chinese Hamster Ovary (CHO) cells for the production of biologics.
- These transposases allow for creative approaches to genetic engineering without being constrained by the limitations associated with single enzyme usage.
- Using multiple enzymes, ATUM can make orthogonal genetic changes to cell lines, decreasing the risk of destabilizing previous modifications.
- A case study presented by Oren Beske showcased the successful use of three different transposases to modify CHO cells, enabling the production of a uniquely glycosylated antibody.
- Looking forward, ATUM plans to develop a versatile protein expression system that employs multiple transposases for both early-stage drug discovery and large-scale manufacturing.
Conclusion:
Incorporating multiple transposase enzymes can significantly enhance the adaptability and complexity of biologic production processes. As the demand for sophisticated biologics grows, ATUM’s advancements indicate a promising shift towards more bespoke manufacturing platforms capable of meeting the challenges of current biotechnological demands.
